

Ourania Nicolatou-Galitis

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/1934097/publications.pdf>

Version: 2024-02-01

32
papers

2,558
citations

257450
24
h-index

414414
32
g-index

32
all docs

32
docs citations

32
times ranked

3306
citing authors

#	ARTICLE	IF	CITATIONS
1	Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale. <i>Quality of Life Research</i> , 2022, 31, 841-853.	3.1	3
2	Oral Complications of Head and Neck Cancer Therapy. <i>Forum of Clinical Oncology</i> , 2021, 12, 52-66.	0.2	2
3	The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab. <i>Supportive Care in Cancer</i> , 2020, 28, 177-184.	2.2	4
4	Nivolumab-related lichen planus of the lip in a patient with head and neck cancer. <i>Oral Oncology</i> , 2020, 104, 104623.	1.5	11
5	Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. <i>Oral Diseases</i> , 2020, 26, 955-966.	3.0	43
6	Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019, 27, 3985-3995.	2.2	76
7	Workshop of European task force on medication-related osteonecrosis of the jaw "Current challenges. <i>Oral Diseases</i> , 2019, 25, 1815-1821.	3.0	104
8	International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV. <i>Head and Neck</i> , 2019, 41, 1725-1737.	2.0	69
9	Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. <i>Supportive Care in Cancer</i> , 2019, 27, 383-394.	2.2	85
10	Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2019, 127, 117-135.	0.4	198
11	A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer. <i>Supportive Care in Cancer</i> , 2018, 26, 1905-1915.	2.2	46
12	Osteonecrosis of the jaw (ONJ) in patients who receive Bone Targeting Agents (BTAs): the power of e-learning. <i>Eancermedalscience</i> , 2018, 12, ed77.	1.1	5
13	Osteonecrosis of the jaw in a patient with acute myeloid leukemia, who received azacitidine. <i>Journal of Cancer Metastasis and Treatment</i> , 2016, 2, 220.	0.8	8
14	Measuring quality of life in patients with head and neck cancer: Update of the EORTC QLQ-H&N Module, Phase III. <i>Head and Neck</i> , 2015, 37, 1358-1367.	2.0	65
15	Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015, 120, 699-706.	0.4	29
16	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2014, 120, 1453-1461.	4.1	838
17	International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. <i>Quality of Life Research</i> , 2014, 23, 825-836.	3.1	67
18	Performance of the EORTC questionnaire for the assessment of quality of life in head and neck cancer patients EORTC QLQ-H&N35: a methodological review. <i>Quality of Life Research</i> , 2013, 22, 1927-1941.	3.1	66

#	ARTICLE	IF	CITATIONS
19	Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 116, e110-e116.	0.4	25
20	Systematic review of amifostine for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 2013, 21, 357-364.	2.2	89
21	Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 2013, 21, 3179-3189.	2.2	95
22	Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy "Update of the EORTC QLQ-H&N35, Phase I. Head and Neck, 2013, 35, 1331-1338.	2.0	27
23	Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012, 113, 234-238.	0.4	60
24	Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2011, 112, 195-202.	1.4	70
25	Oral Mucositis, Pain and Xerostomia in 135 Head and Neck Cancer Patients Receiving Radiotherapy with or without Chemotherapy. The Open Cancer Journal, 2011, 4, 7-17.	0.2	17
26	A systematic review of oral fungal infections in patients receiving cancer therapy. Supportive Care in Cancer, 2010, 18, 985-992.	2.2	211
27	Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositis. Supportive Care in Cancer, 2006, 14, 753-762.	2.2	39
28	Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Supportive Care in Cancer, 2006, 14, 44-51.	2.2	56
29	Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection. Oral Oncology, 2003, 39, 397-401.	1.5	30
30	Gingival Overgrowth as the Initial Paraneoplastic Manifestation of Hodgkin's Lymphoma in a Child. A Case Report. Journal of Periodontology, 2001, 72, 107-112.	3.4	6
31	Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwash. Journal of Oral Pathology and Medicine, 2001, 30, 471-480.	2.7	54
32	The oral manifestations of chronic graft-versus-host disease (cGVHD) in paediatric allogeneic bone marrow transplant recipients. Journal of Oral Pathology and Medicine, 2001, 30, 148-153.	2.7	60